



News Release

Suven presenting at Windhover's Bio/Pharma Partnerships conference in San Francisco

HYDERABAD, INDIA (December 11, 2007) – Suven Life Sciences Ltd (Suven) announces today that Mr. Venkat Jasti, Vice Chairman and CEO will present Suven's Drug Discovery Pipeline at Windhover's Bio/Partnerships conference in San Francisco on Dec 13th. Windhover's Bio/Pharma Partnerships, is an exclusive partnering conference that links global biotechnology and pharmaceutical companies to explore potential Collaborations, M&A, Alliances and financing activities.

The conference provide **platform for the most promising innovator companies** to present their companies which are handpicked by Windhover's Information Inc. In addition to presenting at this conference, Suven will be holding one-to-one meeting with various senior-level dealmakers for collaborations, Financing initiatives and alliances.

Suven has been working on innovative technology platforms particularly in the class of selective 5-HT compounds for development as therapeutic agents in the treatment of neuro-degenerative disorders like **Alzheimer's, Attention deficient hyperactivity, Huntington's, Parkinson and Schizophrenia and Obesity** .

Suven thus far **has filed 26 product patents** under PCT out of which 10 has entered national phase. So far **36 product patents were granted from 12 countries**. Suven has already filed its first **Investigational New Drug (IND)** application with DCGI to conduct the clinical Phase-I study on their developmental candidate **SUVN-502**.

We continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential, says Venkat Jasti, CEO of Suven.

Suven, since Sept-2006 is also working as a **collaborative Research Partner (CRP)** with Elli Lilly to Discover and Develop NCEs for an unmet medical need in CNS therapeutic area.

Suven is a major service provider of Drug Discovery and Development support Services (**DDDSS**) to global Pharmaceutical, Life Sciences and Biotech companies in addition to their continued business interest and growth in Contract Research and Manufacturing Services (**CRAMS**).

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;